| Clinical data | |
|---|---|
| AHFS/Drugs.com | monograph |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | subcutaneous (once daily) |
| Pharmacokinetic data | |
| Bioavailability | 90% for Anti-Xa activity, 67% for Anti-IIa activity)[1] |
| Metabolism | primarily by liver by desulfation and/or depolymerization |
| Half-life | 200 min. for Anti-Xa activity, 257. min for Anti-IIa activity [2] |
| Identifiers | |
| CAS number | 9005-49-6 [9041-08-1] (sodium salt) |
| ATC code | B01AB10 |
| UNII | 3S182ET3UA |
| KEGG | D07510 |
| ChEMBL | CHEMBL1201414 |
| Chemical data | |
| Formula | ? |
| Mol. mass | 6500 (average)[3] |
| (what is this?) (verify) |
|
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis and pulmonary embolism.[4] Tinzaparin sodium is the only low molecular weight heparin shown to be safe in pregnancy and in critically ill people with renal failure at both treatment and prophylaxis dose levels.[5]
It can be given subcutaneously by syringe, or intravenously.[6] it is manufactured by Leo pharmacutical company
Contents |
In the United States, tinzaparin is FDA approved for the following indications:
Tinzaparin is approved for the following
In July 2008, the company revised the prescribing information to restrict the use of tinzaparin in patients 90 years of age or older. FDA is concerned that the preliminary data from the IRIS study suggests that the increased risk of mortality is not limited only to patients 90 years of age or older.
According to the study Innohep increases the risk of death for elderly patients (i.e., 70 years of age and older) with renal insufficiency. Healthcare professionals should consider the use of alternative treatments to Innohep when treating elderly patients over 70 years of age with renal insufficiency and DVT, PE, or both.
(note the previous version of this article made a crucial error by removing the not from the sentence ...the increased risk of mortality is not limited only to patients 90 years of age... This revision corrects this and gives more detail of the advice..
Also see the Health Canada website. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2010/innohep_hpc-cps-eng.php
No LMWH, except tinzaparin, is licensed for use in gestational hypercoagulability.[7] Still, tinzaparin is often the LMWH of choice in pregnant women.[7]
Bleeding in overdose. There is occasionally bruising at the site of injection.
Tinzaparin does NOT affect the international normalized ratio (INR), prothrombin time (PT) Anti-factor Xa levels can be measured, and are often used to monitor tinzaparin
Protamine sulfate will reverse Tinzaparin by 85% per package insert.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||